Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$32.91
Change (%) Stock is Up 1.04 (3.26%)
Volume491,572
Data as of 05/25/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
05/07/18The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke
Inclisiran reduced key atherogenic lipoproteins – found in the blood of individuals at high risk of heart attacks – back to normal in 68% to 90% of patient studied Inclisiran drove sustained lowering of key atherogenic lipoproteins – non-HDL-C, ApoB, VLDL-C and Lp(a) Pre-specified analysis of ORION-1 Phase II study featured in late-breaking session at 86th Annual European Atherosclerosis Society Congress Analysis acc... 
Printer Friendly Version
04/30/18The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
–Data shows inclisiran has a one-size-fits-all dosing regimen of 300 mg on Day-1, Day-90 and every six months thereafter across a wide range of dyslipidemia patient populations and sub-groups– PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2018-- The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las ... 
Printer Friendly Version
04/25/18The Medicines Company Reports First-Quarter 2018 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 25, 2018-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018. “During the first quarter of 2018, The Medicines Company continued to demonstrate strong clinical and operational execution, significantly advancing the ORION development programs for our investigational agent, inclisiran, and delivering against all of our other 2018 objectives,” ... 
Printer Friendly Version
04/19/18The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 19, 2018-- The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments. The conference call may be accessed by telephone as follows: U.S./Canada:     ... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.